Hims & Hers Health Inc (NYSE:HIMS) has seen its stock drop 21% to $25.73 over the past month, driven by regulatory updates from the FDA regarding tirzepatide injection shortages. However, the stock remains up over 200% over the past year, reflecting strong earnings performance.
What To Know: The company reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations of 4 cents. Revenue rose 77% year-over-year to $401.6 million, beating estimates of $382.2 million.
Subscriber growth surged 44%, reaching 2 million, and net income soared to $75.6 million, compared to a net loss of $7.6 million last year. However, gross margins narrowed slightly to 79%, down from 83% a year ago.
CEO Andrew Dudum highlighted the company's continued momentum, noting its focus on delivering accessible, personalized care. Hims & Hers raised its fiscal 2024 revenue outlook to $1.46-$1.465 billion, indicating confidence in sustained growth.
Investor sentiment has otherwise been tempered over the past month by the FDA's resolution of the tirzepatide shortage, which may pressure demand for compounded alternatives. Despite this, ongoing shortages of other GLP-1 drugs and strong fundamentals could position Hims & Hers for potential long-term success.
How To Buy HIMS Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange-traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Hims & Hers Health's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, Hims & Hers has a 52-week high of $35.02 and a 52-week low of $8.14.
It closed Wednesday down more than 7% at $25.73.
在过去的一个月中，Hims & Hers Health Inc（纽约证券交易所代码：HIMS）的股价下跌了21％，至25.73美元，这得益于美国食品药品管理局关于替塞帕肽注射短缺的最新监管消息。但是，该股在过去一年中仍上涨了200％以上，这反映了强劲的收益表现。
须知：该公司在11月公布了令人印象深刻的第三季度业绩，每股收益为32美分，远远超过分析师预期的4美分。收入同比增长77％，达到4.016亿美元，超过预期的3.822亿美元。
订户增长了44％，达到200万，净收入飙升至7560万美元，而去年的净亏损为760万美元。但是，毛利率从去年同期的83％略微缩小至79％。
首席执行官安德鲁·杜杜姆强调了公司的持续发展势头，指出该公司专注于提供可获得的个性化护理。Hims & Hers将其2024财年的收入前景上调至14.6亿至14.65亿美元，这表明了对持续增长的信心。
在过去的一个月中，美国食品药品管理局解决了曲塞帕肽短缺问题，这可能会给复合替代品的需求带来压力，从而抑制了投资者的情绪。尽管如此，其他 GLP-1 药物的持续短缺和强劲的基本面可能使Hims & Hers取得潜在的长期成功。
如何购买 HIMS 股票
除了前往经纪平台购买股票的股票（或部分股票）外，您还可以通过购买本身持有股票的交易所交易基金（ETF）来获得股票，或者将自己分配到401（k）中寻求收购共同基金或其他工具股票的策略。
例如，就Hims & Hers Health而言，它属于医疗保健领域。ETF可能会持有许多有助于追踪该行业的流动性和大型公司的股票，从而使投资者能够了解该细分市场的趋势。
根据Benzinga Pro的数据，Hims & Hers的52周高点为35.02美元，52周低点为8.14美元。
周三收盘下跌超过7％，至25.73美元。
